New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

Lupus is more common in Black people, and symptoms can be different too. Here's what to look out for and how to treat it.

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

HealthDay News — For patients with systemic lupus erythematosus (SLE), obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, is superior to placebo, according to a study published ...

Phase III results put obinutuzumab in line for approval ...

A woman in her 30s presented with generalised swelling and a right occipital–temporal headache. Examination showed grade 4 papilloedema, and magnetic resonance venography revealed thrombosis of the ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Investigators assessed shear wave elastography (SWE) in detecting subclinical renal damage in patients with LN currently in clinical remission.

CNIs are also playing an increasingly visible role in treatment strategies. About one in five LN patients managed by nephrologists, and slightly more among rheumatologists, are currently receiving a ...

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...